Functional polymorphisms in dopamine-related genes: Effect on neurocognitive functioning in HIV+ adults

Journal of Clinical and Experimental Neuropsychology

Volumn 34, Issue 1, 2012, Pages 78-91

  Levine, Andrew J ^a   Sinsheimer, Janet S ^a   Bilder, Robert ^a   Shapshak, Paul ^b   Singer, Elyse J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Brain derived neurotrophic factor; Catechol O methyltransferase; Dopamine transporter; HIV associated neurocognitive disorders; NeuroAIDS; Pharmacogenetic

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CD4 ANTIGEN; DOPAMINE TRANSPORTER;

ADDICTION; ADULT; AGE; AGED; ARTICLE; COGNITIVE DEFECT; FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEARNING; MALE; MIDDLE AGED; MOVEMENT (PHYSIOLOGY); NEUROPSYCHOLOGICAL TEST; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; REGRESSION ANALYSIS; SHORT TERM MEMORY; VIROLOGY;

ADULT; AGE FACTORS; AGED; ANTIGENS, CD4; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; COGNITION DISORDERS; DNA MUTATIONAL ANALYSIS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HIV INFECTIONS; HUMANS; LEARNING; MALE; MEMORY, SHORT-TERM; MIDDLE AGED; MOVEMENT; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84856846162     PISSN: 13803395     EISSN: 1744411X     Source Type: Journal    
DOI: 10.1080/13803395.2011.623118     Document Type: Article

References (79)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., et al. (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology, 69(18), 1789-1799.
3. Arendt, G., & von Giesen, H. J. (2002). Human immunodeficiency virus dementia: Evidence of a subcortical process from studies of fine finger movements. Journal for Neurovirology, 8(Suppl. 2), 27-32.
4. Atkinson, J. H.,Heaton, R. K., Patterson, T. L.,Wolfson, T., Deutsch, R., Brown, S. J., et al. (2008). Two-year prospective study of major depressive disorder in HIVinfected men. Journal of Affective Disorders, 108(3), 225-234.
5. Aylward, E. H., Henderer, J. D., McArthur, J. C., Brettschneider, P. D., Harris, G. J., Barta, P. E., et al. (1993). Reduced basal ganglia volume in HIV-1-associated dementia: Results from quantitative neuroimaging. Neurology, 43(10), 2099-2104.
6. Battery, A. I. T. (1944). Manual of directions and scoring. Washington, DC: War Department, Adjutant General's Office.
7. Benedict, R. H. B., Schretlen, D., Groninger, L., & Dobraski, M. (1996). Revision of the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and validity. Psychological Assessment, 8(2), 145-153.
8. Berger, J. R., & Arendt, G. (2000). HIV dementia: The role of the basal ganglia and dopaminergic systems. Journal of Psychopharmacology, 14(3), 214-221.
9. Berger, J. R., & Nath, A. (1997). HIV dementia and the basal ganglia. Intervirology, 40(2-3), 122-131.
10. Berger, J. R., Nath, A., Greenberg, R. N., Andersen, A. H., Greene, R. A., Bognar, A., et al. (2000). Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology, 54(4), 921-926.
11. Bertolino, A., Blasi, G., Latorre, V., Rubino, V., Rampino, A., Sinibaldi, L., et al. (2006). Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. Journal of Neuroscience, 26(15), 3918-3922.
12. Bilder, R. M., Volavka, J., Czobor, P., Malhotra, A. K., Kennedy, J. L., Ni, X., et al. (2002). Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biological Psychiatry, 52(7), 701-707.
13. Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004). The catechol-O-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology, 29(11), 1943-1961.
14. Bousman, C. A., Cherner, M., Atkinson, J. H., Heaton, R. K., Grant, I., Everall, I. P., et al. (2010). COMT Val158Met polymorphism, executive dysfunction, and sexual risk behavior in the context of HIV infection and methamphetamine dependence. Interdisciplinary Perspectives on Infectious Diseases, 2010, 678648, 1-9.
15. Buchacz, K., McFarland, W., Kellogg, T. A., Loeb, L., Holmberg, S. D., Dilley, J., & Klausner, J. D. (2005). Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS, 19, 1423-1424.
16. Chang, L.,Wang, G. J., Volkow, N. D., Ernst, T., Telang, F., Logan, J., et al. (2008). Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. NeuroImage, 42(2), 869-878.
17. Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. (1996). Neurology, 47(5), 1247-1253.
18. Cysique, L. A., Deutsch, R., Atkinson, J. H., Young, C., Marcotte, T. D., Dawson, L., et al. (2007). Incident major depression does not affect neuropsychological functioning in HIV-infected men. Journal of the International Neuropsychological Society, 13(1), 1-11.
19. Cysique, L.A., Letendre, S. L.,Ake, C., Jin, H., Franklin, D. R., Gupta, S., et al. (2010). Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS, 24(7), 983-990.
20. Cysique, L. A., Maruff, P., & Brew, B. J. (2004). Prevalence and pattern of neuropsychological impairment in human immunodeficiency virusinfected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts. Journal for Neurovirology, 10(6), 350-357.
21. Cysique, L. A., Maruff, P., & Brew, B. J. (2006). Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology, 66(9), 1447-1450.
22. Dal Pan, G. J., McArthur, J. H., Aylward, E., Selnes, O. A., Nance-Sproson, T. E., Kumar, A. J., et al. (1992). Patterns of cerebral atrophy in HIV-1-infected individuals: Results of a quantitative MRI analysis. Neurology, 42(11), 2125-2130.
23. Dantzer, R., & Kelley, K. W. (2007). Twenty years of research on cytokine-induced sickness behavior. Brain, Behavavior, and Immunity, 21(2), 153-160.
24. Doucette-Stamm, L. A., Blakely, D. J., Tian, J., Mockus, S., & Mao, J. I. (1995). Population genetic study of the human dopamine transporter gene (DAT1). Genetic Epidemiology, 12(3), 303-308.
25. Durvasula, R. S., Myers, H. F., Satz, P., Miller, E. N., Morgenstern, H., Richardson, M. A., et al. (2000). HIV-1, cocaine, and neuropsychological performance in African American men. Journal of the International Neuropsychological Society, 6(3), 322-335.
26. Edelstein, H., & Knight, R. T. (1987). Severe parkinsonism in two AIDS patients taking prochlorperazine. The Lancet, 2(8554), 341-342.
27. Egan,M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., et al. (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 98(12), 6917-6922.
28. Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., et al. (2003). The BDNF val66met polymorphism affects activitydependent secretion of BDNF and human memory and hippocampal function. Cell, 112(2), 257-269.
29. Fujimura, R. K., Goodkin, K., Petito, C. K., Douyon, R., Feaster, D. J., Concha, M., et al. (1997). HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 16(3), 146-152.
30. Fujimura, R. K., Khamis, I., Shapshak, P., & Goodkin, K. (2004). Regional quantitative comparison of multispliced to unspliced ratios of HIV-1 RNA copy number in infected human brain. Journal of NeuroAIDS, 2(4), 45-60.
31. Goldberg, T. E., Egan,M. F., Gscheidle, T., Coppola, R., Weickert, T., Kolachana, B. S., et al. (2003). Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Archives of General Psychiatry, 60(9), 889-896.
32. Gordillo, V., del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13(13), 1763-1769.
33. Guillin, O., Diaz, J., Carroll, P., Griffon, N., Schwartz, J. C., & Sokoloff, P. (2001). BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature, 411(6833), 86-89.
34. Hariri, A. R., Goldberg, T. E., Mattay, V. S., Kolachana, B. S., Callicott, J. H., Egan, M. F., et al. (2003). Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. Journal of Neuroscience, 23(17), 6690-6694.
35. Hasin, D. S., Trautman, K. D., Miele, G. M., Samet, S., Smith,M., & Endicott, J. (1996). Psychiatric Research Interview for Substance and Mental Disorders (PRISM): Reliability for substance abusers. The American Journal of Psychiatry, 153(9), 1195-1201.
36. Heaton, R. K., Clifford, D. B., Franklin, D. R., Jr.,Woods, S. P., Ake, C., Vaida, F., et al. (2010). HIVassociated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology, 75(23), 2087-2096.
37. Heaton, R. K., Grant, I., & Matthews, C. G. (1991). Comprehensive norms for an expanded Halstead-Reitan battery: Demographic corrections, research findings, and clinical implications. Odessa, FL: Psychological Assessment Resources.
38. Hinkin, C. H., van Gorp, W. G., Mandelkern, M. A., Gee, M., Satz, P., Holston, S., et al. (1995). Cerebral metabolic change in patients with AIDS: Report of a six-month follow-up using positron-emission tomography. Journal of Neuropsychiatry and Clinical Neurosciences, 7(2), 180-187.
39. Hintze, J. (2008). PASS 2008. NCSS, LLC.Kaysville,UT: NCSS. Retrieved from http://www.ncss.com.
40. Hsieh, P. C., Yeh, T. L., Lee, I. H., Huang, H. C., Chen, P. S., Yang, Y. K., et al. (2010). Correlation between errors on the Wisconsin Card Sorting Test and the availability of striatal dopamine transporters in healthy volunteers. Journal of Psychiatry and Neuroscience, 35(2), 90-94.
41. Itoh, K.,Mehraein, P., &Weis, S. (2000). Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathologica (Berlin), 99(4), 376-384.
42. Kieburtz, K. D., Epstein, L. G., Gelbard, H. A., & Greenamyre, J. T. (1991). Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Archives of Neurology, 48(12), 1281-1284.
43. Klove, H. (1963). Clinical neuropsychology. In F. M. Forster (Ed.), Medical clinics of North America. New York, NY: Saunders.
44. Koutsilieri, E., Sopper, S., Scheller, C., ter Meulen, V., & Riederer, P. (2002). Parkinsonism in HIV dementia. Journal of Neural Transmission, 109(5-6), 767-775.
45. Kumar, A. M., Fernandez, J., Singer, E. J., Commins, D.,Waldrop-Valverde, D., Ownby, R. L., et al. (2009). Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. Journal for Neurovirology, 15(3), 1-18.
46. Kumar, A. M., Ownby, R. L., Waldrop-Valverde, D., Fernandez, B., & Kumar, M. (2011). Human immunodeficiency virus infection in the CNS and decreased dopamine availability: Relationship with neuropsychological performance. Journal for Neurovirology, 17(1), 26-40.
47. Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y. M., Szumlanski, C. L., & Weinshilboum, R. M. (1996). Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 6(3), 243-250.
48. Leserman, J. (2008). Role of depression, stress, and trauma in HIV disease progression. Psychosomatic Medicine, 70(5), 539-545.
49. Levine, A. J., Singer, E. J., Sinsheimer, J. S., Hinkin, C. H., Papp, J., Dandekar, S., et al. (2009). CCL3 genotype and current depression increase risk of HIV-associated dementia. Neurobehavioral HIV Medicine, 1, 1-7.
50. Li, X., Margolick, J. B., Conover, C. S., Badri, S., Riddler, S. A., Witt, M. D., et al. (2005). Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. Journal of Acquired Immune Deficiency Syndromes, 38(3), 320-328.
51. Malhotra, A. K., Kestler, L. J., Mazzanti, C., Bates, J. A., Goldberg, T., & Goldman, D. (2002). A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. The American Journal of Psychiatry, 159(4), 652-654.
52. Mattay, V. S., Goldberg, T. E., Fera, F., Hariri, A. R., Tessitore, A., Egan, M. F., et al. (2003). Catechol Omethyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proceedings of the National Academy of Sciences of the United States of America, 100(10), 6186-6191.
53. Mocchetti, I., Nosheny, R. L., Tanda, G., Ren, K., & Meyer, E. M. (2007). Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. Annals of the New York Academy of Sciences, 1122, 144-154.
54. Morgello, S., Gelman, B. B., Kozlowski, P. B., Vinters, H. V., Masliah, E., Cornford, M., et al. (2001). The National NeuroAIDS Tissue Consortium: A new paradigm in brain banking with an emphasis on infectious disease. Neuropathology and Applied Neurobiology, 27(4), 326-335.
55. Mossner, R., Daniel, S., Albert, D., Heils, A., Okladnova, O., Schmitt, A., et al. (2000). Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochemistry International, 36(3), 197-202.
56. Mozley, L. H., Gur, R. C.,Mozley, P. D., & Gur, R. E. (2001). Striatal dopamine transporters and cognitive functioning in healthy men and women. The American Journal of Psychiatry, 158(9), 1492-1499.
57. National Center for Biotechnology Information (2011). dbSNP. Retrieved from http://www.ncbi.nlm.nih.gov/projects/SNP/ (accessed October 12, 2011).
58. Navia, B. A., Jordan, B. D., & Price, R. W. (1986). The AIDS dementia complex: I. Clinical features. Annals of Neurology, 19(6), 517-524.
59. Nolan, K. A., Bilder, R. M., Lachman, H. M., & Volavka, J. (2004). Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: Differential effects of Val and Met alleles on cognitive stability and flexibility. American Journal of Psychiatry, 161(2), 359-361.
60. Nosheny, R. L., Ahmed, F., Yakovlev, A., Meyer, E. M., Ren, K., Tessarollo, L., et al. (2007). Brainderived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo. European Journal of Neuroscience, 25(8), 2275-2284.
61. Nosheny, R. L., Mocchetti, I., & Bachis, A. (2005). Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration. Neurotoxicity Research, 8(1-2), 187-198.
62. Pezawas, L., Verchinski, B. A., Mattay, V. S., Callicott, J. H., Kolachana, B. S., Straub, R. E., et al. (2004). The rain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. Journal of Neuroscience, 24(45), 10099-10102.
63. Power, C., Kong, P. A., Crawford, T. O., Wesselingh, S., Glass, J. D., McArthur, J. C., et al. (1993). Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations of the blood-brain barrier. Annals of Neurology, 34(3), 339-350.
64. Prata, D. P., Mechelli, A., Fu, C. H., Picchioni, M., Toulopoulou, T., Bramon, E., et al. (2009). Epistasis between the DAT 3′ UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 106(32), 13600-13605.
65. Raison, C. L., Capuron, L., & Miller, A. H. (2006). Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends in Immunology, 27(1), 24-31.
66. Rippeth, J. D., Heaton, R. K., Carey, C. L., Marcotte, T. D., Moore, D. J., Gonzalez, R., et al. (2004). Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. Journal of the International Neuropsychological Society, 10(1), 1-14.
67. Rosa, A., Peralta, V., Cuesta, M. J., Zarzuela, A., Serrano, F., Martinez-Larrea, A., et al. (2004). New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. The American Journal of Psychiatry, 161(6), 1110-1112.
68. Rottenberg, D. A., Sidtis, J. J., Strother, S. C., Schaper, K. A., Anderson, J. R., Nelson, M. J., et al. (1996). Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. Journal of Nuclear Medicine, 37(7), 1133-1141.
69. Shapiro, A. M., Benedict, R. H., Schretlen, D., & Brandt, J. (1999). Construct and concurrent validity of the Hopkins Verbal Learning Test-Revised. Clinical Neuropsychology, 13(3), 348-358.
70. Stein, D. J. (2008). Depression, anhedonia, and psychomotor symptoms: The role of dopaminergic neurocircuitry. CNS Spectrums, 13(7), 561-565.
71. Tomasi, D., Chang, L., de Castro Caparelli, E., Telang, F., & Ernst, T. (2006). The human immunodeficiency virus reduces network capacity: Acoustic noise effect. Annals of Neurology, 59(2), 419-423.
72. van Gorp, W. G., Mandelkern, M. A., Gee, M., Hinkin, C. H., Stern, C. E., Paz, D. K., et al. (1992). Cerebral metabolic dysfunction in AIDS: Findings in a sample with and without dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 4(3), 280-287.
73. VanNess, S. H., Owens, M. J., & Kilts, C. D. (2005). The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genetics, 6, 55. doi:10.1186/1471-2156-6-55
74. Wang, G. J., Chang, L., Volkow, N. D., Telang, F., Logan, J., Ernst, T., et al. (2004). Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain, 127(11), 2452-2458.
75. Wechsler, D. (1997). Wechsler Adult Intelligence Scale-III. San Antonio, TX: The Psychological Corporation.
76. Wiens, A. N., Fuller, K. H., & Crossen, J. R. (1997). Paced Auditory Serial Addition Test: Adult norms and moderator variables. Journal of Clinical and Experimental Neuropsychology, 19(4), 473-483.
77. Wiley, C. A., & Nelson, J. A. (1990). Human immunodeficiency virus: Infection of the nervous system. Current Topics in Microbiology and Immunology, 160, 157-172.
78. Woods, S. P., Moore, D. J., Weber, E., & Grant, I. (2009). Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychology Review, 19(2), 152-168.
79. Woods, S. P., Rippeth, J.D., Frol,A. B., Levy, J. K.,Ryan, E., Soukup, V. M., et al. (2004). Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. Journal of Clinical and Experimental Neuropsychology, 26(6), 759-778.